Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480665 | 1.00 | CHRM1 (0.42) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5486546 | 0.92 | GRM1 (0.42) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5486552 | 0.92 | GRM1 (0.42) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5481568 | 0.91 | CHRM1 (0.42) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5481574 | 0.91 | CHRM1 (0.42) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5485424 | 0.88 | KIT (0.44) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5485428 | 0.88 | KIT (0.44) | CHRM1CHRM4CHRM2CHRM3GRM1 | |
| SCHEMBL5480698 | 0.87 | GRM1 (0.56) | GRM1L3MBTL1 | |
| SCHEMBL5480694 | 0.87 | GRM1 (0.56) | GRM1L3MBTL1 | |
| SCHEMBL5483917 | 0.82 | GRM1 (0.42) | GRM1L3MBTL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | CHRM1 177/4885CHRM4 230/4885CHRM2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.